Tenatoprazole

Source: Wikipedia, the free encyclopedia.
Tenatoprazole
Clinical data
Routes of
administration		Oral
ATC code
  • none
Pharmacokinetic data
MetabolismHepatic (CYP2C19-mediated)
Elimination half-life4.8 to 7.7 hours
Identifiers
  • 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-imidazo[4,5-b]pyridine
JSmol)
ChiralityRacemic mixture
  • Cc1c(OC)c(C)cnc1CS(=O)c2[nH]c3ccc(OC)nc3n2
  • InChI=1S/C16H18N4O3S/c1-9-7-17-12(10(2)14(9)23-4)8-24(21)16-18-11-5-6-13(22-3)19-15(11)20-16/h5-7H,8H2,1-4H3,(H,18,19,20) checkY
  • Key:ZBFDAUIVDSSISP-UHFFFAOYSA-N checkY
  (verify)

Tenatoprazole is a

peptic ulcer as far back as 2003.[1] The compound was invented by Mitsubishi Tanabe Pharma and was licensed to Negma Laboratories (part of Wockhardt as of 2007[2]).[3]
: 22 

Mitsubishi reported that tenatoprazole was still in Phase I clinical trials in 2007[4]: 27  and again in 2012.[3]: 17 

Tenatoprazole has an imidazopyridine ring in place of the benzimidazole moiety found in other proton pump inhibitors, and has a half-life about seven times longer than other PPIs.[5]

See also

References

  1. ^ "Gastrointestinal Disease Update". Digestive Disease Week. DataMonitor. March 2003.
  2. ^ "Investors unwilling to forgive Wockhardt, promoter for failings". Economic Times. 3 March 2011.
  3. ^ a b "State of New Product Development" (PDF). Mitsubishi Tanabe Pharma. 8 May 2012.
  4. ^ "FY2007 Interim Financial Results". Mitsubishi Tanabe Pharma.
  5. S2CID 44647770
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Tenatoprazole&oldid=1148403883"